Tag Archives: amgn

Amgen Refuses To Split, But Plans Hearten Investors

Big-cap biotech Amgen (AMGN) offered 2015 guidance, set 2018 targets and resisted pressure to split at a business-review meeting Tuesday. On the heels of Monday’s Q3 earnings beat, Amgen’s action helped drive the stock up more than 5% in afternoon trading on the stock market today to a new high above 156. Amgen guided 2015 revenue at $20.8 billion to $21.3 billion, above analyst consensus of $20.4 billion. It guided EPS at $9.05 to $9.40, beating

Amgen Q3 Earnings Beat Estimates; Guidance Mixed

Big-cap biotech Amgen (AMGN) beat Wall Street’s third-quarter estimates and guided full-year earnings a bit above consensus Monday, sending its recently hot stock up 1% in after-hours trading. Amgen’s earnings excluding one-time items rose 19% over the year-ago quarter to $2.30 a share, beating analysts’ consensus by 19 cents, according to Thomson Reuters. Sales increased 6% to $5.03 billion, about $70 million ahead of estimates. On the conference

Amgen Cancer Drug Kyprolis Succeeds In Trial

Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in the stock market today, a modest rise as investors await results from an important second trial. The first trial, called ASPIRE, studied multiple-myeloma patients who’d already relapsed after one